Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMP · Real-Time Price · USD

3.970

-0.200 (-4.80%)

At close: Jul 29, 2026, 4:00 PM EDT

3.960

-0.010 (-0.25%)

After-hours: Jul 29, 2026, 5:55 PM EDT

Oramed Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	109.97	64.02	-19.1	5.09	-37.76	-12.26
Depreciation & Amortization	0.12	0.12	0.19	0.2	0.06	0.02
Stock-Based Compensation	5.54	5.99	4.05	4.22	11.53	1.78
Other Adjustments	-140.4	-77.37	3.25	-17.1	-0.8	0.04
Changes in Accounts Payable	1.46	1.13	3.53	-2.23	-0.38	0.69
Changes in Unearned Revenue	-2	-2.11	-	-1.34	-0.7	-0.9
Changes in Other Operating Activities	-1.11	-0.93	-0.33	0.87	0.14	-0.48
Operating Cash Flow	-8.54	-9.15	-8.41	-10.3	-27.92	-11.12
Operating Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-0.01	-0.01	-0.02	-0.25	-0.5	-0.01
Sale of Property, Plant & Equipment	-	-	-	-	0.02	-
Purchases of Investments	-65.71	-88.51	-55.76	-190.92	-154.41	-100
Proceeds from Sale of Investments	42.4	103.13	161.66	118.14	185.09	0.76
Other Investing Activities	-11.92	-9.17	-0.07	-	0	-
Investing Cash Flow	-37.66	5.44	105.82	-73.04	30.21	-99.25

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Long-Term Debt Issued	-	-	-	99.55	-	-
Long-Term Debt Repaid	-	-	-49.55	-50	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-49.55	49.55	-	-
Issuance of Common Stock	-	-	-	2.43	11.56	60.57
Repurchase of Common Stock	-	-4.74	-2.48	-	-	-
Net Common Stock Issued (Repurchased)	-	-4.74	-2.48	2.43	11.56	60.57
Common Dividends Paid	-10.36	-	-	-	-	-
Other Financing Activities	-	-	-0	-	-0.78	-
Financing Cash Flow	-15.11	-4.74	-52.04	51.98	10.78	60.57

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.01	-0.03	-0	-0.05	-0.06	0.01
Net Cash Flow	-61.31	-8.47	45.37	-31.41	13.01	-49.79

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-8.55	-9.15	-8.43	-10.55	-28.41	-11.13
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-	-457.70%	-	-787.24%	-1051.20%	-1231.31%
Free Cash Flow Per Share	-0.20	-0.22	-0.21	-0.26	-0.73	-0.29
Levered Free Cash Flow	70.16	62.26	-65.24	52.32	-37.94	10.98
Unlevered Free Cash Flow	-14.64	-14.62	-11.96	-18.52	-42.09	11.64

SEC Filings: 10-K · 10-Q